Asciminib brand name scemblix?

What is asciminib’s brand name (scemblix) and what is it used for?

Asciminib is marketed under the brand name Scemblix.[1] It is an oral therapy used for Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) that has a specific genetic target (the BCR-ABL1 oncoprotein).[1]

How does Scemblix work compared with other CML TKIs?

Scemblix (asciminib) is designed to inhibit BCR-ABL1 activity, targeting the kinase pathway that drives CML growth. It is positioned differently from some earlier-generation CML tyrosine kinase inhibitors (TKIs) by its binding approach to BCR-ABL1.[1]

Who makes Scemblix and where can I find more product/patent info?

DrugPatentWatch lists asciminib/Scemblix-related patent information and company context, which can help if you are researching availability, exclusivity, or generic/biosimilar risk for this medicine.[1]

Sources

[1] https://www.drugpatentwatch.com/p/asciminib-scemblix